# Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery

> **NCT06204159** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 12 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Neuroendocrine Tumors

## Interventions

- **DEVICE:** TACE Catheters

## Key facts

- **NCT ID:** NCT06204159
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204159, "Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06204159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*